• LaFleur Minerals has engaged FMI Securities and FM Global Markets to raise up to C$5 million in debt financing.
• The capital will be used to restart production at their fully permitted Beacon Gold Mill in Val-d’Or, Québec.
• The company also launched two equity offerings: a LIFE private placement and a charity flow-through unit offering, which together could raise over C$5.4 million in additional capital.
• LaFleur’s strategy focuses on near-term production at its Beacon Gold Mill, sourcing material from the Swanson Gold Deposit and other surrounding projects, highlighted by current gold prices and production-ready infrastructure as key advantages.

LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0), a Canadian near-term gold producer, is moving forward with its plans to restart gold production at its wholly owned Beacon Gold Mill by securing corporate finance advisors and expanding its capital-raising efforts (https://ibn.fm/O5qUa).

On July 25, the company announced it had engaged FMI Securities Inc. and FM Global Markets Inc. to raise up to C$5 million in secured debt financing. If acquired, these funds would be earmarked for restarting operations at the Beacon Gold Mill, a fully permitted and recently refurbished facility located in Val-d’Or, Quebec, positioned on Canada’s largest gold producing greenstone belt. FMI Securities is registered in Ontario, while FM Global Markets is a U.S.-based FINRA-registered dealer. The arrangement gives LaFleur access to both Canadian and U.S. capital markets.

The engagement lasts 180 days and includes a non-refundable C$25,000 work fee, plus a 4% commission on gross proceeds raised. A reduced 2% fee applies to investors on LaFleur’s pre-approved list. If the company completes a debt financing without the agents during the agreement term, a C$50,000 break fee is payable.

In parallel, LaFleur is offering up to C$2.88 million in units through a non-brokered private placement using the listed issuer financing exemption, known as the “LIFE Offering.” Each unit includes one common share and one warrant exercisable at C$0.75 for 24 months. Warrants are subject to accelerated expiry if the stock closes at or above C$0.90 for 14 consecutive trading days.

The company is also pursuing a C$2.59 million charity flow-through offering to support exploration spending at its Swanson Gold Project. Each unit in this offering consists of one flow-through share and one warrant with the same terms as the LIFE Offering. These proceeds will qualify as “flow-through mining expenditures” under Canadian and Québec tax laws.

The two equity offerings are expected to close this month. LaFleur will pay qualified brokers a 7% cash commission and issue an equal number of broker warrants for the LIFE Offering.

In a recent interview featured on IBN’s MiningNewsWire podcast, LaFleur CEO Paul Ténière and Chairman Kal Malhi discussed the company’s short-term production strategy and its long-term positioning (https://ibn.fm/MXTdz).

“We’re an interesting company in the fact that we have an advanced gold project in Québec’s Abitibi Gold Belt and a nearby permitted mill,” Ténière said. “That puts us in a strong position as a near-term gold producer.”

The district-scale Swanson Gold Project, recently expanded, now spans more than 18,000 hectares, and includes a current mineral resource estimate. LaFleur also holds an existing mining lease at the site, enabling faster production timelines. The company’s plan is to process material from Swanson at the Beacon Gold Mill, which has a capacity of over 750 tonnes per day.

Malhi, who also heads Bullrun Capital, explained how LaFleur acquired its core assets via bankruptcy proceedings. “We were able to win a bid on the Beacon Gold Mill, which Monarch had invested $20 million into upgrading. It’s fully permitted and ready to rock,” he said. “We also acquired a nearby gold deposit called the Swanson Gold Deposit… We’ve turned that project into LaFleur Minerals. Now, with gold prices surging, the economics have changed phenomenally — and we may look at producing not just from our own property, but also from others in the region.”

Ténière added that today’s high gold prices create favorable conditions for restarting operations and accelerating project timelines. “We have a mining lease at Swanson, which allows us to get into production much faster than we could otherwise,” he said. “With gold hitting over $3,000 an ounce, it makes a lot of these deposits potentially economically viable… It’s an exciting time to be in gold, and we’re in a great position to move quickly.”

For more information, visit the company’s website at LaFleurMinerals.com.

Qualified Person Statement:

All scientific and technical information contained in this article has been reviewed and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the company and considered a Qualified Person for the purposes of NI 43-101.

NOTE TO INVESTORS: The latest news and updates relating to LFLRF are available in the company’s newsroom at ibn.fm/LFLRF

• Interconnected network of AI agents fundamentally transforms how marketing agencies create value and scale their impact
• The infrastructure will be introduced in three key phases: operational streamlining, strategic enablement and creative augmentation
• ONAR’s sees collaboration as foundational to the company’s long-term vision of building an advanced AI-powered agency system

ONAR Holding Corp. (OTCQB: ONAR), a marketing technology company focused on AI-powered growth solutions, has announced the expansion of its strategic partnership with IQSTEL Inc. (NASDAQ: IQST) and IQSTEL’s artificial intelligence subsidiary, Reality Border (ibn.fm/whT2b). The collaboration will lead to the development and phased rollout of a multiagentic operating infrastructure designed to support ONAR’s internal teams and client services with a secure, scalable and highly automated system powered by AI.

“This initiative is about amplifying human potential with AI—not replacing it,” said ONAR Holding Claude Zdanow (ibn.fm/loQzr). “We are investing in intelligent systems that help our teams move faster, think smarter, and achieve superior outcomes for our clients. This interconnected network of AI agents fundamentally transforms how marketing agencies create value and scale their impact.”

According to agreement, IQSTEL will embed specialized AIRWEB AI agents within ONAR company operations and client accounts, enabling automation of repetitive tasks while preserving data security, brand integrity and creative oversight. The text-based assistants require no additional infrastructure and provide ONAR’s commercial team with real-time insights, campaign intelligence and operational efficiency.  Built with strict security protocols, the platform will not retain or store proprietary data, ensuring compliance and data integrity.

The infrastructure will be introduced in three key phases: operational streamlining, strategic enablement and creative augmentation. During these phases, AI agents will increasingly integrate into key workflows, progressing from task-based automation to collaborative intelligence that supports high-level marketing strategy and content development. This phased approach allows ONAR to scale the platform in alignment with real-time business needs and ensure continuous optimization.

ONAR’s leadership sees this collaboration with IQSTEL and Reality Border as foundational to the company’s long-term vision of building an advanced AI-powered agency system. This is an evolution of the company’s proprietary Cortex platform, which already serves as the foundation for performance marketing, media planning and data analysis across ONAR’s agency network. By integrating multiagent architecture into Cortex, ONAR intends to redefine how marketing services are delivered, emphasizing speed, efficiency and intelligent automation without sacrificing creative and strategic depth.

The partnership also leverages IQSTEL’s telecommunications expertise and Reality Border’s AI architecture to create a uniquely capable infrastructure that bridges marketing technology with enterprise-grade AI. ONAR emphasized that the initiative is not about replacing human talent but rather enhancing it with tools that enable teams to deliver better results, faster and more efficiently. 

ONAR Holding Corp. is building a new kind of marketing organization, one that blends traditional agency services with AI-first technology. Its agency network includes specialized units such as Storia (performance marketing), Of Kos (healthcare marketing) and ONAR Labs (technology incubation). This structure allows the company to serve a range of mid-market clients, typically those generating between $50 million and $1 billion in annual revenue, across industries including CPG, healthcare and retail.

ONAR’s business model is also unique: Instead of billing by the hour or based on ad spend, the company offers fixed-rate access to creative and campaign services across multiple platforms. This “platform-first” model allows clients to scale without cost escalation, while ONAR remains focused on delivering measurable business results. With campaigns currently running on more than 20 platforms, the company is positioned to deliver integrated, data-driven marketing at scale — and now, with the multiagentic AI system in place, at greater speed and efficiency.

This AI infrastructure initiative, made possible through the expanded IQSTEL partnership, marks a key step in ONAR’s strategy to lead the next era of marketing, an era driven by intelligent systems, collaborative automation and performance-aligned service models. This groundbreaking initiative also signals a broader movement in the industry toward agentic operations, where teams are empowered by AI not only to do more but to do it smarter. 

For more information, visit the company’s website at www.ONAR.com.

NOTE TO INVESTORS: The latest news and updates relating to ONAR are available in the company’s newsroom at https://ibn.fm/ONAR

• Izotropic’s IzoView Breast CT Imaging System represents a breakthrough in dedicated breast imaging technology, addressing persistent limitations in conventional screening methods through proprietary hardware and software
• FDA regulatory pathway alignment clears the path for a pivotal U.S. clinical study, with the company completing a comprehensive 150-page strategic business plan and advanced financial modeling for commercialization
• Strategic awareness initiatives including dedicated breastct.com platform and podcast series position the company for market education as breast CT technology emerges as the next generation of cancer detection

The medical community stands at the threshold of what could become the most significant advancement in cancer detection since the introduction of mammography over half a century ago. While survival rates for many cancers have improved dramatically through better treatments, the fundamental challenge of early detection remains largely unchanged. Current screening technologies, despite decades of refinement, still miss cancers in their earliest, most treatable stages, while simultaneously generating false positives that lead to unnecessary anxiety and interventions.

This detection gap represents more than a technological limitation; it reflects a fundamental constraint in how we approach cancer screening. Traditional imaging methods were technologies designed for general diagnostic purposes and later adapted for cancer detection, creating inherent compromises in sensitivity, specificity, and patient experience. The result is a screening paradigm that, while valuable, leaves substantial room for improvement in the precise detection capabilities needed to identify cancers when they are most curable.

Recent advances in computational imaging, artificial intelligence, and dedicated diagnostic hardware have converged to create unprecedented opportunities for purpose-built cancer detection systems. Unlike incremental improvements to existing technologies, these innovations enable entirely new approaches to imaging that can detect abnormalities with greater precision while reducing both missed cancers and false positives.

The potential impact extends beyond improved detection rates to fundamentally changing the cancer care paradigm from treatment-focused to prevention-focused, where early identification enables intervention before cancers progress to advanced stages.

That transformation potential is exactly what Izotropic (CSE: IZO) (OTCQB: IZOZF) is pursuing through its development of dedicated breast imaging technology designed specifically for next generation cancer detection.

Purpose-Built Technology Addresses Fundamental Screening Limitations

Izotropic’s competitive advantage lies in its commitment to developing CT imaging technology, specifically engineered for breast applications while addressing limitations of general-purpose and legacy screening systems. Breast CT Imaging System represents a ground-up approach to breast imaging, incorporating proprietary hardware innovations and software elements, and is optimized for next-generation AI integrations specifically for breast cancer detection.

The dedicated breast CT approach offers several advantages over conventional mammography and even competing breast imaging technologies. By utilizing three-dimensional imaging capabilities specifically designed for breast tissue analysis, IzoView can potentially identify abnormalities that traditional two-dimensional mammography might miss due to tissue overlap or density masking.

Izotropic’s exclusive worldwide licensing agreement with the Regents of the University of California provides the foundation for this technological approach. The revised licensing agreement, requiring FDA approval or a foreign equivalent by specified timelines aligned with the Company’s commercialization plans, demonstrates the company’s commitment to bringing this technology through regulatory approval and into clinical practice.

Regulatory Pathway Validation Enables Clinical Advancement

Izotropic’s confirmation of regulatory alignment with the FDA represents a critical milestone that positions the company for clinical study initiation and eventual market authorization. The pre-submission meeting process and formal meetings on regulatory strategy and clinical study design provide the framework needed to advance IzoView through the approval process.

This regulatory clarity is particularly significant given the complexity of medical device approval pathways. FDA alignment on both regulatory strategy and clinical study design reduces uncertainty around the approval process while providing a clear roadmap for the clinical evidence needed to demonstrate safety and efficacy.

The company’s completion of a comprehensive 150-page strategic business plan and sophisticated financial modeling demonstrates the depth of preparation for commercialization beyond regulatory approval. These materials integrate multi-year projections, capital requirements, and scenario-based analysis across various clinical and commercial settings, providing the strategic framework needed for successful market entry.

“The plan provides detailed market intelligence, competitive positioning, clinical and regulatory execution frameworks, and tailored go-to-market strategies across priority U.S. and international healthcare markets,” according to the company’s recent corporate update.

Market Education Strategy Builds Foundation for Adoption

Izotropic’s strategic awareness initiatives recognize that successful commercialization of breakthrough medical technology requires comprehensive market education alongside regulatory approval. The company’s multi-platform approach addresses different stakeholder groups with targeted information designed to build understanding and support for dedicated CT technology.

The forthcoming launch of breastct.com as a dedicated educational platform will evolve with the company as it progresses toward commercialization, ultimately providing a centralized resource for patients, clinicians, and advocates seeking information about breast CT technology and its advantages over conventional imaging methods. This educational foundation is essential for market adoption, as healthcare providers and patients need to understand the benefits of new imaging approaches to drive utilization.

The accompanying podcast series offers another communication channel for delivering updates on corporate developments, clinical milestones, and regulatory progress while providing context around broader trends in breast imaging and medical technology. This consistent communication approach helps build stakeholder engagement throughout the development and commercialization process.

These awareness efforts complement the company’s investor outreach initiatives, which utilize tailored materials derived from the strategic business plan to engage sophisticated investors and institutional stakeholders interested in funding clinical studies and commercialization strategy.

Positioning for Transformational Impact

Izotropic’s development of purpose-built breast imaging technology positions the company at the forefront of what could become a fundamental shift in cancer detection capabilities. As the medical community increasingly recognizes the limitations of conventional screening approaches, dedicated imaging technologies designed specifically for cancer detection offer the potential for significantly improved outcomes.

The combination of proprietary technology development, regulatory pathway clarity, comprehensive commercialization planning, and strategic market education creates a foundation for successful advancement from clinical development through market adoption.

If successful, IzoView could represent more than an incremental improvement in breast imaging; it could exemplify the type of purpose-built imaging technology needed to make early-stage cancer detection significantly more effective, potentially transforming breast cancer from a treatment challenge to a prevention opportunity.

For more information, visit the company’s website at www.IzoCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF

• LaFleur Minerals has begun a fully funded, 5,000-metre diamond drilling campaign at its Swanson Gold Project in Quebec.
• All required drilling permits have been received, including Forestry Intervention and Authorization to Intervene.
• Independent valuation pegs Beacon Gold Mill’s replacement cost at over C$71.5 million; Mill rehabilitation and commissioning estimated at C$4.1 million, presenting a low-cost path to near-term production.
• The company has expanded its land package to over 18,300 hectares, reinforcing its district-scale potential.

LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0), a Canadian near-term gold producer, has initiated diamond drilling at its Swanson Gold Project in the prolific Abitibi region of Quebec, following receipt of key permits. The program, covering at least 5,000 metres of drilling, is focused on priority targets within the Swanson Gold Deposit and other promising zones, including Bartec, Jolin, and Marimac. According to the company, these zones were identified through detailed geological and geophysical work, including magnetic surveys, induced polarization (“IP”), and soil geochemistry analysis (https://ibn.fm/KGilj).

Drilling has already begun, and will test key structural, geological, geochemical and geophysical anomalies for additional gold mineralization potential, with additional details and assay results expected in the coming weeks.

At the same time, LaFleur completed an independent valuation of its Beacon Gold Mill, located in Val-d’Or. The evaluation, conducted by Bumigeme Inc., concluded that the mill is in “excellent condition.” Estimated rehabilitation and re-commissioning costs were pegged at C$4.1 million. Bumigeme’s report also calculated that the total cost to replace the mill, tailings facility, and permitting would exceed C$71.5 million, significantly more than the capital required to bring the current facility online. The mill’s C$4.1 million restart compared to C$71.5 million replacement value underscores its strong asset value and strategic importance, where restart is highly cost-efficient, pivoting LaFleur quickly into the region’s new vertically-integrated producer.

The Beacon Gold Mill, already fully permitted and capable of processing 750 tonnes per day, with potential to expand capacity over time, represents a potential advantage in a region with numerous advanced exploration and development-stage gold projects that could use closely located processing capability. Since the mill sits among over 100 active and historical mining sites, it offers both logistical and operational synergies, moreover, its proximity to the Swanson Gold Project (approximately 50 km away) enhances its strategic role in processing locally sourced mineralized material from its own assets, which potentially boosts margins and enhances control. LaFleur plans to integrate the mill’s valuation into an upcoming Preliminary Economic Assessment (“PEA”) for the Swanson project.

Beyond its mill asset, LaFleur continues to build scale in its exploration footprint. The company recently staked an additional 32 mineral claims, extending the Swanson Project’s area to 18,304 hectares across 445 claims and one mining lease. This expansion increases the project’s strike length to over 33 kilometres and consolidates control over a major structural break in the Abitibi region. 

This structural corridor hosts a range of gold occurrences, including the Swanson, Bartec, and Jolin deposits, and has been the site of more than 36,000 metres of historical drilling. LaFleur’s ongoing work aims to integrate legacy data with new high-resolution surveys to define new mineralization zones. 

LaFleur Minerals CEO Paul Ténière said the company was very pleased with the results of the evaluation as it truly shows the milling asset’s potential. “Our technical team has also done an exceptional job integrating historical exploration data with new geophysical and geochemical datasets to define compelling drilling targets at Swanson. Receiving the required permits clears the way for us to advance one of the most exciting exploration and drilling campaigns in the region,” Ténière added. “Not only are we launching a fully funded, data-driven drilling program, but we’ve also strategically expanded our land position in a way that meaningfully increases our discovery potential.”

The next step for the company is to secure the necessary financing to complete the rehabilitation and re-commissioning of the Beacon Gold Mill, with the aim to complete the mill restart program by early 2026.

For more information, visit the company’s website at LaFleurMinerals.com.

Qualified Person Statement:

All scientific and technical information contained in this article has been reviewed and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the Company and considered a Qualified Person for the purposes of NI 43-101.

NOTE TO INVESTORS: The latest news and updates relating to LFLRF are available in the company’s newsroom at ibn.fm/LFLRF

• Breast cancer continues to be the most commonly diagnosed cancer among U.S. women, excluding nonmelanoma skin cancer
• Izotropic is preparing to revolutionize breast cancer imaging with its flagship IzoView Breast CT Imaging System
• In anticipation of future commercialization, Izotropic is initiating a strategic awareness and engagement campaign

Accurate detection and diagnosis remain critical challenges in the fight against breast cancer, especially for women with dense breast tissue where mammography falls short. Izotropic (CSE: IZO) (OTCQB: IZOZF) is at the forefront of addressing these gaps through its IzoView Breast CT Imaging System, a contrast-enhanced CT platform designed for enhanced screening precision. The company is actively preparing for the commercialization of IzoView, signaling a pivotal development in breast cancer imaging.

Breast cancer continues to be the most diagnosed cancer among U.S. women (excluding nonmelanoma skin cancer), with approximately 316,950 new cases of invasive breast cancer expected in women in 2025, along with 2,800 cases in men (ibn.fm/zRTJQ). The disease remains the second-leading cause of cancer-related death among women, with more than 42,000 women and 510 men projected to die of breast cancer this year (ibn.fm/jNdXe).

Despite advances in early detection and treatment, only about 66% of cases are diagnosed at a localized stage, when five-year survival rates can exceed 99% (ibn.fm/mwubn). Women with dense breast tissue, nearly half of those in the United States, face higher risk and lower detection rates using conventional mammography and tomosynthesis, which are less sensitive in dense tissue (ibn.fm/CNkv3).

Given these disparities, the need for improved screening, diagnostic accuracy and treatment guidance is urgent. Dense breast tissue not only elevates cancer risk but also masks tumors under traditional 2D imaging, often resulting in delayed detection and treatment. While survival rates are encouraging overall, outcomes worsen substantially when cancers are diagnosed at regional or distant stages, where five-year survival drops significantly. This underscores a critical unmet medical need for diagnostic tools that reliably detect cancers regardless of tissue density and provide earlier, more actionable clinical insight.

Against this backdrop, Izotropic is preparing to revolutionize breast cancer imaging with its flagship IzoView Breast CT Imaging System, a dedicated breast imaging platform offering high-resolution, true 3D visualization without breast compression. According to the company, the system was advanced from academic innovation to commercial readiness by its expert in-house team using exclusively licensed technology that was developed at the University of California, Davis. The platform system, which integrates proprietary mechanical design, patented hardware innovations, optimizes diagnostic accuracy, patient comfort and clinical workflow. The company also has proprietary AI-driven enhancements protected as trade secrets to support radiologist performance.

In anticipation of future commercialization, Izotropic is initiating a strategic awareness and engagement campaign (ibn.fm/Zu0b5). The company’s efforts will center on a consistent and compelling stream of development-related news to educate global audiences on the transformative value of dedicated breast CT technology and will spotlight how IzoView stands apart from traditional breast imaging modalities and competing breast CT systems, positioning it as a true game-changer in the field.

In addition, the company will also launch a new podcast and new website: breastct.com, a dedicated educational hub aimed at informing patients, clinicians and advocates about breast CT technology and its advantages over standard imaging. This outreach initiative includes a steady stream of development-related updates intended to raise global awareness of IzoView’s potential to reshape breast imaging workflows and improve outcomes. By sharing research, regulatory progress, and technical differentiation, Izotropic is working to establish IzoView as a new standard in breast cancer screening.

Taken together, the breadth of breast cancer incidence, the substantial mortality burden and the limitations of current screening technologies make the case for innovation unmistakable. Izotropic’s IzoView system, and its thoughtful regulatory and educational strategy, stand poised to address long-standing gaps in detection and diagnosis. As the company moves toward securing regulatory approval following a successful FDA pre-submission and eventual clinical study for PMA submission, IzoView may offer a breakthrough tool that empowers earlier detection, reduces false negatives, and ultimately helps save lives. 

For more information, visit the company’s website at www.IzoCorp.com

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF

• Survey by Wakefield Research and D-Wave shows 46% of surveyed business leaders expect $1 million to $5 million ROI from quantum optimization within the first year of adoption.
• 81% believe they have reached the limits of classical computing’s capabilities for optimization.
• 53% are planning to integrate quantum computing into their workflows, while 27% are considering it.
• Quantum optimization is seen as especially valuable in logistics, supply chain, manufacturing, planning and inventory, and R&D.
• 88% of participants said their organizations would “go above and beyond” for even a 5% improvement in optimization.

A new survey released by D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, suggests that quantum computing is gaining traction as a business tool, particularly for optimization problems. The findings point to a growing belief among surveyed decision-makers that classical computing may no longer be sufficient for the operational challenges they face (https://ibn.fm/YPAsc).

Conducted by Wakefield Research, the survey queried 400 business leaders from North America, Europe, and the Asia-Pacific region in May 2025. Respondents were decision-makers from industries such as logistics, manufacturing, life sciences, financial services, and retail; sectors where optimization is central to business success.

According to the study, 46% of respondents whose companies have already implemented quantum optimization or plan to do so within the next two years expect a return on investment of between $1 million and $5 million within the first 12 months. Another 27% predict a return of over $5 million during the same period.

A large majority of surveyed business leaders, 81%, believe they have reached the limits of what classical computing can deliver for optimization problems. These limitations appear to be pushing interest toward alternatives. Fifty-three percent of respondents reported they are planning to integrate quantum computing into their operational workflows, with another 27% considering doing so. 

The study highlights optimization as a focal point for quantum adoption. Key potential quantum optimization use cases cited include supply chain and logistics (50%), manufacturing (38%), planning and inventory (36%), and research and development (36%).

Importantly, 88% of participants said their organizations would “go above and beyond” for even a 5% improvement in optimization. This was especially true for participants in the manufacturing sector, where efficiency gains often translate directly to cost savings and margin improvements.

Companies continue to face hurdles when it comes to optimization. Respondents cited outdated technology (39%), budget constraints (38%), dependency on classical optimization on conventional computers (36%), and talent or skills shortages (35%) as key barriers. In addition, 87% acknowledged that internal complacency could be hindering innovation.

When asked about quantum’s usefulness in addressing specific operational problems, 60% of all respondents, and 73% of those most familiar with quantum optimization technology, said they expect it to be very or extremely helpful. Nearly a quarter in the latter group called quantum a “game changer” for their business operations.

According to D-Wave CEO Dr. Alan Baratz, the shift toward quantum optimization is no longer just about future potential—it’s about solving “business-critical problems now,” and this is something D-Wave is already doing with its quantum computing technologies. 

“Yesterday’s legacy computing solutions are struggling to keep pace with modern business,” said Dr. Baratz. “Leaders are increasingly recognizing that annealing quantum computing can play a pivotal role in solving business-critical problems now. This survey reflects the rapidly growing interest in applying quantum to complex optimization use cases, with business leaders unequivocally recognizing the substantial potential ROI of doing so.”

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our quantum computers — the world’s largest — feature QPUs with sub-second response times and can be deployed on-premises or accessed through our quantum cloud service, which offers 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our quantum systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

• The trial targets never-smoker non-small cell lung cancer (“NSCLC”) patients, a group with limited treatment options.
• Japan’s high incidence of never-smoker NSCLC makes it a strategic region for the trial.
• LP-300 is being tested alongside standard chemotherapy agents in patients who have relapsed after tyrosine kinase inhibitor therapy.
• Lantern’s AI-driven approach may help identify and accelerate development of therapies in underserved cancer markets.
• Additional trial data from Taiwan and the U.S. is expected later in Q3 2025.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC(TM) clinical trial evaluating investigational drug candidate LP-300 in never-smoker non-small cell lung cancer (“NSCLC”) patients (https://ibn.fm/JXFqG).

The company enrolled 10 patients across five sites in Japan, including the National Cancer Center in Tokyo, ahead of its internal timeline. The milestone underscores Lantern Pharma’s international strategy to focus on regions with a higher prevalence of never-smoker NSCLC cases, an under-addressed patient population with no approved treatments specifically targeting their form of lung cancer.

Lantern Pharma’s HARMONIC trial is evaluating LP-300 in combination with standard chemotherapy (carboplatin and pemetrexed) for patients who have previously relapsed after treatment with tyrosine kinase inhibitors (“TKIs”). The Japanese arm of the trial represents one part of a broader multinational study also enrolling patients in the United States and Taiwan.

Lantern Pharma CEO and President Panna Sharma described the enrollment success as a validation of the company’s focus on regions where never-smoker NSCLC is most prevalent. “Completing our targeted enrollment in Japan ahead of schedule demonstrates excellent execution of our international expansion strategy and validates our decision to focus on regions where never-smoker NSCLC has the highest prevalence,” said Sharma. “This achievement builds momentum as we continue enrollment in Taiwan and the United States, bringing us closer to generating the clinical data that could establish LP-300 as a treatment option for this underserved patient population with significant unmet medical need.”

In Japan, 33-40% of new NSCLC cases occur in never-smokers, a rate more than twice that of the U.S. or Europe, where the figure typically falls around 15%. In Taiwan, more than half of lung cancer cases are found in never-smokers. Lantern Pharma’s trial strategy is built around these regional disparities.

The HARMONIC trial is designed to enroll around 90 patients and includes overall survival (“OS”) and progression-free survival (“PFS”) as its primary endpoints. Initial results from a U.S. cohort showed an 86% clinical benefit rate and a 43% objective response rate among the first seven patients. One patient experienced a durable complete response in target cancer lesions, with survival now nearing two years (https://ibn.fm/5PJ3T).

LP-300, a disulfide small molecule, has a multimodal mechanism of action. It interacts with cell redox enzymes and modifies tyrosine kinase receptors, critical components in cancer cell growth and resistance pathways. The compound has already been tested in multiple Phase 1-3 trials involving over 1,000 subjects, with retrospective analyses suggesting a survival advantage in never-smoker lung adenocarcinoma patients.

No therapies are currently approved specifically for never-smoker NSCLC. This makes Lantern’s work in this space a potentially valuable asset in the oncology drug development market. The company estimates the global market opportunity for treating never-smoker NSCLC exceeds $4 billion annually.

The potential value is compounded by Lantern Pharma’s AI-driven drug development platform, RADR(R). The platform analyzes large volumes of oncology data, more than 100 billion data points and 200+ machine learning algorithms, to identify molecular targets, refine trial design, and reduce the time and cost of oncology drug development. The company’s pipeline includes other AI-discovered or AI-enhanced oncology candidates. In March 2024, Lantern dosed patients in a Phase 1a/1b trial for LP-284, an agent targeting relapsed or refractory non-Hodgkin’s lymphoma.

Lantern Pharma has signaled openness to partnership or licensing discussions for LP-300 to support commercialization across different geographies. The company expects to provide additional trial updates, including data from Taiwan and the U.S., before the end of the third quarter of 2025.

For more information, visit the company’s website at www.LanternPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

• Lantern Pharma has introduced an AI-powered module within its RADR(R) platform to assess DDA-DDRi combination therapies.
• The module uses genomic, transcriptomic, and clinical data, to predict treatment synergy and patient response, and supported the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer.
• A review of 221 clinical trials informed the development of the predictive algorithm.
• Non-PARP DDRi combinations with DNA-damaging agents showed strong outcomes in specific cancer subtypes.
• Lantern is evaluating licensing opportunities to commercialize the module for broader oncology use.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has unveiled a new artificial intelligence module designed to predict the effectiveness of cancer treatment combinations involving DNA-damaging agents (“DDAs”) and DNA damage response inhibitors (“DDRis”). The technology is integrated into the company’s RADR(R) platform, which supports AI-guided drug development.

The launch comes at a time when the global market for combination cancer therapies is projected to surpass $50 billion by 2030, according to Lantern’s announcement (https://ibn.fm/3ZspZ).

The new module draws on multi-omics data – genomic, transcriptomic, and clinical –and applies machine learning models to predict which DDA-DDRi combinations are likely to produce synergistic effects in specific patient subgroups. Lantern says this approach can help design more effective, less toxic treatments and reduce development timelines and costs by up to one-third.

Panna Sharma, Lantern’s CEO and president, said the AI module aims to streamline the development of tailored cancer therapies. “This AI-powered module is a transformative step in our mission to deliver personalized cancer treatments,” said Sharma. “By leveraging our RADR(R) platform to analyze complex multi-omics and clinical trial data, we identified optimal DDA-DDRi combinations that guided the development of our TNBC trial. We believe this approach could reduce combination therapy development timelines and costs by one-third compared to traditional methods.”

The system’s predictive capabilities are underpinned by a peer-reviewed study published in Frontiers in Oncology that examined 221 clinical trials involving DDA-DDRi regimens (https://ibn.fm/MvmkB). From these, 89 trials with interpretable outcomes were scored based on effectiveness, safety, and biomarker-driven responses. This data was then used to train the AI model, which classifies agents into 8 DDA and 14 DDRi subclasses.

Among the study’s findings, non-PARP DDRi combinations, especially those involving WEE1 inhibitors like adavosertib paired with platinum agents, showed an 80% positive outcome rate in interstrand cross-linker trials. This approach may hold particular promise for cancers with TP53 mutations, which are often difficult to treat.

The module also highlights how biomarker profiling can improve patient selection. For example, TP53 mutations and homologous recombination deficiency (“HRD”) signatures emerged as key predictors of drug response. In some regimens, reformulated drugs helped reduce toxicity. Liposomal doxorubicin, a variant with lower cardiotoxicity, was identified as a safer option for combination strategies.

Lantern has already applied the module’s insights to the design of its current clinical programs. Notably, the RADR(R) platform informed the company’s FDA-cleared Phase 1B/2 trial testing LP-184 and olaparib in triple-negative breast cancer (“TNBC”), a subtype with limited treatment options and high unmet need.

According to the company, the AI module’s architecture includes multiple specialized agents that aggregate data, classify compounds, identify biomarkers, and model outcomes. Its design allows it to evolve with new inputs, making it a continuously learning system.

Lantern is also exploring potential licensing agreements to bring the tool to a broader range of research institutions and biotech firms. The company believes the AI module could accelerate the pace of combination therapy development across various cancer types.

By embedding this technology into RADR(R), Lantern Pharma continues to position itself as a developer of data-driven approaches to oncology drug development. The module not only improves the chances of clinical success but also aligns with growing industry efforts to personalize cancer treatments based on molecular and genetic profiles.

For more information, visit the company’s website at www.LanternPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

• The FDA-cleared HeartBeam system enables patients and physicians to access significant arrhythmia data outside traditional clinical settings.
• The HeartBeam system, credit card–sized and fully portable, represents a breakthrough in ambulatory cardiac care. 
• Beyond ambulatory arrhythmia assessment, the platform is poised for future advancements, including synthesized 12-lead ECG generation.

Foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system has proved pivotal for HeartBeam (NASDAQ: BEAT), a cardiac technology company focused on transforming the cardiac-care space (https://ibn.fm/0TAG4). The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system enables patients and physicians to access critical arrhythmia data outside traditional clinical settings.

The HeartBeam system, credit card–sized and fully portable, represents a breakthrough in ambulatory cardiac care. The device, which is equipped with five electrodes and records three-directional electrical signals over a 30-second period, is the first of its kind to receive FDA clearance in December 2024. When a patient experiences symptoms, the accompanying smartphone app walks them through capturing a recording. The recorded data is transmitted via the cloud, reviewed by a physician within the context of symptoms and medical history, and used to direct timely care. This capability significantly reduces diagnostic delays and enables proactive management of arrhythmias.

“It’s well documented that patients who delay seeking care for their cardiac symptoms face worse clinical outcomes,” said HeartBeam CEO Robert Eno. “The ability for patients to capture high-fidelity ECG signals from three distinct directions wherever they are when symptoms occur will help patients get the care they need in a timelier manner. The foundational FDA clearance of our technology for arrhythmia assessment is a significant milestone for the company that brings us one step closer to fulfilling our vision of providing unprecedented cardiac insights to individuals and physicians.”

According to the company, the initial clearance paves the way for HeartBeam to initiate an Early Access Program, allowing patients and physicians to evaluate the system ahead of its commercial launch. This program is designed to refine user experience and workflow while providing real-world feedback ahead of broader market entry.

Beyond ambulatory arrhythmia assessment, the platform is poised for future advancements, including synthesized 12-lead ECG generation. HeartBeam’s proprietary personalized transformation matrix allows the system to convert the three-directional signals into a synthesized 12-lead ECG, a feature that is expected to provide access to actionable information, enabling physicians to direct patients to timely, appropriate care. The 12-lead ECG synthesis software is currently under FDA review with clearance anticipated later this year.

The company is also developing AI-powered algorithms to enhance arrhythmia detection; early data suggests promising improvements in identifying atrial flutter and other rhythm disturbances, with performance in some cases surpassing cardiologists. HeartBeam plans to submit its AI algorithms for FDA clearance in the future. 

HeartBeam’s technology is underpinned by a robust intellectual property portfolio, which now includes more than 20 issued U.S. and international patents, as well as 2 allowed patents and 32 pending patents (https://ibn.fm/JT9mB). HeartBeam is now building upon the FDA clearance, with a clear runway toward commercial deployment in arrhythmia diagnostics and beyond.

As HeartBeam progresses toward broader clinical adoption, its focus remains on integrating patient-generated ECG data into daily care pathways. Remote monitoring and telehealth platforms stand to benefit from this innovation, particularly in managing chronic cardiac conditions and minimizing hospital readmissions. HeartBeam’s technology aligns with the growing movement toward decentralized, intelligent diagnostics.

With the foundational FDA clearance secured, HeartBeam plans to expand access through early access programs, deploy field-testing among medical practices and ultimately commercialize the system. The anticipated sequence of steps includes physician training, system support and data collection to streamline regulatory and commercial readiness. With a transformative roadmap in place, HeartBeam is positioned to redefine the future of cardiac care, taking it outside the hospital and putting it into the hands of patients and clinicians alike.

For more information, visit HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high
• Nutriband is developing Aversa(TM), a proprietary abuse-deterrent transdermal technology designed to prevent diversion, misuse, abuse and accidental exposure
• Nutriband’s Aversa(TM) fentanyl patch is estimated to have a market potential of $80 million to $200 million annually within five years of launch  

Developing safe, effective and abuse-deterrent delivery systems for controlled substances such as fentanyl is a formidable challenge, and Nutriband (NASDAQ: NTRB) is positioning itself at the forefront of that effort. The company is pioneering transdermal technologies to deliver medications that require careful balancing of patient access with strong mitigation against misuse.

Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high. Fentanyl is approximately 50 times more potent than heroin, and even trace amounts can be fatal, making it a dangerous ingredient when diverted or misused (ibn.fm/0eIOJ). Traditional opioid formulations, including extended-release patches and pills, have frequently been targets for tampering and abuse, leading the FDA to mandate risk management programs and abuse-deterrent formulations (“ADF”) that can help reduce misuse without compromising legitimate patient care (ibn.fm/hgJ0P).

The central difficulty lies in achieving the delicate balance: preventing abuse while preserving patient access for those legitimately in need. Abuse-deterrent technologies are designed to thwart crushing, dissolving or extracting the active drug for illicit use, particularly via injection or snorting. While they cannot eliminate all forms of misuse, they serve as a vital tool in limiting harm and encouraging safe use under medical supervision.

Healthcare providers and regulators like note that ADFs must be combined with comprehensive strategies including monitoring, prescribing oversight and patient education. For drug developers, creating a delivery platform that ensures therapeutic efficacy without enabling tampering is a complex scientific and regulatory challenge. Formulation must be stable, bioavailable and amenable to large-scale manufacturing while reliably deterring common abuse modes.

This is where Nutriband enters the scene. Nutriband is developing Aversa(TM), a proprietary abuse-deterrent transdermal technology designed to prevent diversion, misuse, abuse and accidental exposure. Applied as a coating on fentanyl patches, Aversa introduces aversive agents that discourage tampering and unauthorized use while maintaining steady, controlled delivery for pain patients (ibn.fm/stX9e). The strategy supports patient access by enabling effective chronic pain management with lower systemic exposure and sustained-release characteristics.

Nutriband is collaborating with Kindeva Drug Delivery to manufacture its AVERSA(TM) fentanyl patch. Kindeva has validated that this aversive coating can be applied using standard commercial transdermal production methods, a major step toward scale-up and regulatory compliance (ibn.fm/c6tua). Notably, the FDA’s 505(b)(2) regulatory pathway may allow Nutriband to rely significantly on existing safety and efficacy data for fentanyl patches, potentially reducing the need for extensive phase 2 and 3 trials and accelerating market access (ibn.fm/9ihPI).

The broader impact is significant. Nutriband’s leadership recognizes that fentanyl misuse remains a top contributor to opioid-related overdose deaths. By embedding abuse deterrence in a transdermal format, the company offers an option aiming to deliver pain relief responsibly. Nutriband’s Aversa fentanyl patch is estimated to have a market potential of $80 million to $200 million annually within five years of launch (ibn.fm/r7FtN), a forecast that reflects real need among practitioners seeking safer prescribing alternatives.

Beyond fentanyl, Nutriband’s transdermal platform has broader applicability. Its clinical subsidiary, 4P Therapeutics, is working on formulations for buprenorphine, methylphenidate, peptides, and biologics — all candidates for safe, patch-based delivery. This positions Nutriband to leverage its transdermal expertise across multiple therapeutic areas, potentially transforming how many medications are administered, and how patients adhere to treatment.

Nutriband’s efforts illustrate the significant role that drug-delivery innovation plays in today’s pharmaceutical landscape. By integrating abuse-deterrent strategies into transdermal platforms, Nutriband seeks to improve outcomes for chronic pain patients and reduce the societal burden of opioid misuse, a challenging but potentially transformative contribution to public health. 

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB